Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Promising Data Leads to Expansion of Noxopharm’s LuPIN Trial (ASX:NOX)

LuPIN trial to recruit additional 24 patients Additional patients to be treated with Veyonda? 1200 mg The objective is to see whether the dose-response effect seen to date will lead...read more

Noxopharm’s LuPIN Trial Demonstrates High Rates of Response (ASX:NOX)

Data published today describes positive interim results from the LuPIN trial Veyonda? (NOX66) dose-finding study 69% combined PSA response rate is higher than that observed in studies of ...read more

Noxopharm Announces DARRT Six Month Interim Data Shows Lasting Disease Control (ASX:NOX)

Long-lasting responses with Veyonda + low-dose radiotherapy in late-stage prostate cancer High proportion of disease control following a single, short course of treatment Complete resolution ...read more

Noxopharm, Veyonda and Immuno-Oncology Effect Explained (ASX:NOX)

Noxopharm Limited (ASX:NOX) (‘Noxopharm’ or the ‘Company’) is pleased in response to shareholder enquiry to provide some context around its recent announcement of Veyonda? an...read more

Noxopharm, Appendix 4C- March 2019 Quarter (ASX:NOX)

Veyonda clinical program continuing on plan CEP and DARRT programs to be expanded and expedited on basis of positive clinical data Pending release of DARRT-1 and LuPIN-1 interim clinical data...read more

Noxopharm Limited Changes to Board Structure (ASX:NOX)

Change in Noxopharm Limited Board Structure Dr Graham Kelly appointed Executive Chairman Mr Peter Marks appointed Non-Executive Deputy Chairman Dr Beata Niechoda appointed Specia...read more

Noxopharm Announces Idronoxil Confirmed as a New Immuno-Oncology Drug (ASX:NOX)

New class of immuno-oncology drug identified Activator of NK cells and CD4+ immune cells Potential to boost function of current immuno-oncology drugs. SYDNEY, April 16, 2019: Noxopharm (AS...read more

Noxopharm Announces Veyonda Chemotherapy Enhancement Program to be Expanded (ASX:NOX)

Expansion based on Final Report for Phase 1b CEP-1 study confirming positive efficacy signals in late-stage cancers U.S. study to investigate Veyonda + doxorubicin in sarcomas CEP-2 target st...read more

Noxopharm, KZA: Kazia sells stake in Noxopharm (ASX:NOX)

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an arrangement to sell the remainder of its...read more

Noxopharm, New Corporate Presentation Released (ASX:NOX)

Noxopharm (NOX: ASX) today releases an updated corporate presentation ahead of non-deal roadshow presentations planned over the coming month in the U.S., Hong Kong and China. This is part of the Com...read more

Noxopharm, Appendix 4D and Half Year Accounts (ASX:NOX)

To view the report, download the attached PDF.

Noxopharm to Expedite Veyonda Clinical Program (ASX:NOX)

Internal strategic review triggered by growing confidence in Veyonda becoming a major new anti-cancer drug and the need to confirm commercial and clinical strategies Confirmed aim to develop Veyo...read more

Noxopharm, FNN interview with Nox Chief Medical Officer on Interim Data (ASX:NOX)

Noxopharm (ASX: NOX) presents a Finance News Network (FNN) interview with its Chief Medical Officer, Dr Greg van Wyk, following the release of interim data for its DARRT-1 clinical trial in late-sta...read more

Noxopharm Announces Combination of Veyonda plus Radiotherapy Delivers Clinical Benefits (ASX:NOX)

- Interim (12-week) DARRT-1 readout - Combination Veyonda + low-dose radiotherapy well tolerated - PSA, pain and tumour responses at higher doses - 24-week readout to indicate longevity of re...read more

Noxopharm, December 2018 Quarterly Report Appendix 4C (ASX:NOX)

Veyonda clinical program continuing on plan Imminent release of interim DARRT-1 clinical data DARRT program to be expanded and expedited based on early data LuPIN-1 data to be released mi...read more

Viewing: 76 - 90 of 169 Previous | Next